Cargando…
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631700/ https://www.ncbi.nlm.nih.gov/pubmed/35171976 http://dx.doi.org/10.1182/bloodadvances.2021006555 |
| _version_ | 1784823872264077312 |
|---|---|
| author | Qualls, David Lam, Hiu Ying Whiting, Karissa Kumar, Anita Matasar, Matthew Owens, Colette Nichols, Chelsea Espeleta, James A Qiu, Annie Subzwari, Sarima Biggar, Erin Seshan, Venkatraman Salles, Gilles Younes, Anas Batlevi, Connie |
| author_facet | Qualls, David Lam, Hiu Ying Whiting, Karissa Kumar, Anita Matasar, Matthew Owens, Colette Nichols, Chelsea Espeleta, James A Qiu, Annie Subzwari, Sarima Biggar, Erin Seshan, Venkatraman Salles, Gilles Younes, Anas Batlevi, Connie |
| author_sort | Qualls, David |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9631700 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96317002022-11-04 A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma Qualls, David Lam, Hiu Ying Whiting, Karissa Kumar, Anita Matasar, Matthew Owens, Colette Nichols, Chelsea Espeleta, James A Qiu, Annie Subzwari, Sarima Biggar, Erin Seshan, Venkatraman Salles, Gilles Younes, Anas Batlevi, Connie Blood Adv Research Letter American Society of Hematology 2022-09-16 /pmc/articles/PMC9631700/ /pubmed/35171976 http://dx.doi.org/10.1182/bloodadvances.2021006555 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Qualls, David Lam, Hiu Ying Whiting, Karissa Kumar, Anita Matasar, Matthew Owens, Colette Nichols, Chelsea Espeleta, James A Qiu, Annie Subzwari, Sarima Biggar, Erin Seshan, Venkatraman Salles, Gilles Younes, Anas Batlevi, Connie A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title | A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title_full | A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title_fullStr | A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title_full_unstemmed | A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title_short | A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| title_sort | phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631700/ https://www.ncbi.nlm.nih.gov/pubmed/35171976 http://dx.doi.org/10.1182/bloodadvances.2021006555 |
| work_keys_str_mv | AT quallsdavid aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT lamhiuying aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT whitingkarissa aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT kumaranita aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT matasarmatthew aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT owenscolette aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT nicholschelsea aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT espeletajamesa aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT qiuannie aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT subzwarisarima aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT biggarerin aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT seshanvenkatraman aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT sallesgilles aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT younesanas aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT batleviconnie aphase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT quallsdavid phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT lamhiuying phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT whitingkarissa phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT kumaranita phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT matasarmatthew phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT owenscolette phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT nicholschelsea phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT espeletajamesa phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT qiuannie phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT subzwarisarima phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT biggarerin phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT seshanvenkatraman phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT sallesgilles phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT younesanas phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma AT batleviconnie phase1trialofcopanlisibplusibrutinibinrelapsedrefractorymantlecelllymphoma |